NCT04550494 - Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaClinical Stage III Gastric Cancer AJCC v8Clinical Stage IV Gastric Cancer AJCC v8HER2-Positive Breast CarcinomaLocally Advanced Breast CarcinomaLocally Advanced Gastric CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced Ovarian CarcinomaLocally Advanced Pancreatic CarcinomaLocally Advanced Prostate CarcinomaMetastatic Breast CarcinomaMetastatic Gastric CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Ovarian CarcinomaMetastatic Pancreatic CarcinomaMetastatic Prostate CarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Breast CarcinomaRecurrent Gastric CarcinomaRecurrent Ovarian CarcinomaRecurrent Pancreatic CarcinomaRecurrent Prostate CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Prostate Cancer AJCC v8

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Talazoparib

Given PO

Trial Locations (4)

20892

RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

ACTIVE_NOT_RECRUITING

National Institutes of Health Clinical Center, Bethesda

32610

RECRUITING

University of Florida Health Science Center - Gainesville, Gainesville

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH